• Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions.

AeroVancâ„¢

Savara recently completed enrollment on a Phase IIa clinical study of AeroVanc's safety and efficacy, which was carried out at 40 cystic fibrosis centers throughout the U.S.  Results are expected in Q1-2015.

MRSA in CF

MRSA infections have become increasingly common, with a prevalence of almost 30% of the U.S. cystic fibrosis patient population.